Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658917 · ClinicalTrials.gov registry record
Collecting Solid Tumor Tissue to Identify New Treatments
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 133
- Enrollment target
NCT01658917: Completed study, sponsored by National Cancer Institute (NCI).
NCT01658917 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 133 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01658917 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 133 participants
- Enrollment target
Study Summary
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow tissue samples obtained during the protocol screening process to be used for future and ongoing research in the NCI Surgery Branch Eligibility: Patients must meet the minimum eligibility criteria for an NCI surgery Branch Treatment Protocol Design Patients will undergo testing and evaluations as required by the appropriate NCI Surgery Branch Treatment protocol
Primary Outcome
To collect biologic samples from patients undergoing diagnostic or therapeutic interventions for premalignant, primary or metastatic solid tumors for the purpose of identifying novel molecular and biologic therapeutic targets.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2012-07-24 |
| Est. Completion | 2017-10-23 |
What the finished NCT01658917 record still lists
NCT01658917 is an observational study that tracks outcomes without assigning an intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01658917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01658917 about?
NCT01658917 is a clinical study titled "Collecting Solid Tumor Tissue to Identify New Treatments". Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow tissue samples o...
What is the current status of trial NCT01658917?
This trial is currently completed. The enrollment target is 133 participants. The study started on 2012-07-24. Estimated completion is 2017-10-23.
Who is sponsoring clinical trial NCT01658917?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI